Introduction Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently mutated oncogenes in human cancer​ [1]. Mutations in...

KACTUS is thrilled to announce that our GMP-Grade Cas9 enzyme is playing a pivotal role in the development of Bioheng Therapeutics'...

CD19 remains a hot target in immunotherapy, driving innovation across a range of diseases. This is evidenced by recent approvals...

November 14, 2024 Base Therapeutics announced that its independently developed NK510 cell injection, the world's first base-edited universal NK cell...

With the first CRISPR gene-editing drug approved for over ten months now, what exciting developments are there in CRISPR drug...

Since December 2023, there have been several positive updates about drugs targeting MSLN. On December 19th, RemeGen announced that the...

Since its debut in 2016, base editing technology has opened up new perspectives and methods for drug development with its...

On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001, an anti-HLA-G Chimeric Antigen Receptor-T...

Recently at the 2022 CTOS Conference, Adaptimmune announced the SPEARHEAD-1 clinical trial data of its T cell receptor-engineered T cell...

Chimeric antigen receptor T cell (CAR-T) therapy has been successful in the field of hematological malignancies, but it is not...